The Effects of Acute Alcohol Administration on Circulating Endocannabinoid Levels in Humans

Overview

Journal Addict Biol

Specialty Psychiatry

Date 2022 Aug 24

PMID 36001429

Authors

Matthew E Sloan

Caroline W Grant

Bethany L Stangl

Timothy D Klepp

Honoree W Brewton

Resat Cinar

George Kunos

Vijay A Ramchandani

Affiliations

Soon will be listed here.

Abstract

Several lines of evidence suggest that endocannabinoid signalling may influence alcohol consumption. Preclinical studies have found that pharmacological blockade of cannabinoid receptor 1 leads to reductions in alcohol intake. Furthermore, variations in endocannabinoid metabolism between individuals may be associated with the presence and severity of alcohol use disorder. However, little is known about the acute effects of alcohol on the endocannabinoid system in humans. In this study, we evaluated the effect of acute alcohol administration on circulating endocannabinoid levels by analysing data from two highly-controlled alcohol administration experiments. In the first within-subjects experiment, 47 healthy participants were randomized to receive alcohol and placebo in a counterbalanced order. Alcohol was administered using an intravenous clamping procedure such that each participant attained a nearly identical breath alcohol concentration of 0.05%, maintained over 3 h. In the second experiment, 23 healthy participants self-administered alcohol intravenously; participants had control over their exposure throughout the paradigm. In both experiments, circulating concentrations of two endocannabinoids, N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), were measured at baseline and following alcohol exposure. During the intravenous clamping procedure, acute alcohol administration reduced circulating AEA but not 2-AG levels when compared to placebo. This finding was confirmed in the self-administration paradigm, where alcohol reduced AEA levels in an exposure-dependent manner. Future studies should seek to determine whether alcohol administration has similar effects on brain endocannabinoid signalling. An improved understanding of the bidirectional relationship between endocannabinoid signalling and alcohol intake may deepen our understanding of the aetiology and repercussions of alcohol use disorder.

References

Zimmermann U, OConnor S, Ramchandani V . Modeling alcohol self-administration in the human laboratory. Curr Top Behav Neurosci. 2011; 13:315-53. DOI: 10.1007/7854_2011_149. View

Ramchandani V, Bolane J, Li T, OConnor S . A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol Clin Exp Res. 1999; 23(4):617-23. View

George D, Herion D, Jones C, Phillips M, Hersh J, Hill D . Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl). 2009; 208(1):37-44. PMC: 2963590. DOI: 10.1007/s00213-009-1704-3. View

Sloan M, Gowin J, Yan J, Schwandt M, Spagnolo P, Sun H . Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant. Addict Biol. 2017; 23(1):474-484. PMC: 5538894. DOI: 10.1111/adb.12491. View

Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G . Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci. 2014; 34(8):2822-31. PMC: 6608522. DOI: 10.1523/JNEUROSCI.0849-13.2014. View

Arnone M, Maruani J, Chaperon F, Thiebot M, Poncelet M, Soubrie P . Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1997; 132(1):104-6. DOI: 10.1007/s002130050326. View

Cristino L, Bisogno T, Di Marzo V . Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2019; 16(1):9-29. DOI: 10.1038/s41582-019-0284-z. View

Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhyay B . Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology. 2013; 59(1):143-53. PMC: 3839256. DOI: 10.1002/hep.26606. View

Stangl B, Vatsalya V, Zametkin M, Cooke M, Plawecki M, OConnor S . Exposure-Response Relationships during Free-Access Intravenous Alcohol Self-Administration in Nondependent Drinkers: Influence of Alcohol Expectancies and Impulsivity. Int J Neuropsychopharmacol. 2016; 20(1):31-39. PMC: 5412584. DOI: 10.1093/ijnp/pyw090. View

10.

Mangieri R, Hong K, Piomelli D, Sinha R . An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl). 2009; 205(1):63-72. PMC: 2715164. DOI: 10.1007/s00213-009-1518-3. View

11.

Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J . Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med. 2013; 19(9):1132-40. PMC: 4050982. DOI: 10.1038/nm.3265. View

12.

Ramchandani V, OConnor S, Neumark Y, Zimmermann U, Morzorati S, de Wit H . The alcohol clamp: applications, challenges, and new directions--an RSA 2004 symposium summary. Alcohol Clin Exp Res. 2006; 30(1):155-64. DOI: 10.1111/j.1530-0277.2006.00017.x. View

13.

Soyka M, Koller G, Schmidt P, Lesch O, Leweke M, Fehr C . Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol. 2008; 28(3):317-24. DOI: 10.1097/JCP.0b013e318172b8bc. View

14.

Sloan M, Gowin J, Janakiraman R, Ester C, Stoddard J, Stangl B . High-risk social drinkers and heavy drinkers display similar rates of alcohol consumption. Addict Biol. 2019; 25(2):e12734. PMC: 6717699. DOI: 10.1111/adb.12734. View

15.

Best L, Williams B, Le Foll B, Mansouri E, Bazinet R, Lin L . Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. Neuropsychopharmacology. 2020; 45(8):1289-1296. PMC: 7298050. DOI: 10.1038/s41386-020-0606-2. View

16.

Sloan M, Grant C, Gowin J, Ramchandani V, Le Foll B . Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. Acta Pharmacol Sin. 2018; 40(3):342-350. PMC: 6460371. DOI: 10.1038/s41401-018-0081-z. View

17.

Hirvonen J, Zanotti-Fregonara P, Umhau J, George D, Rallis-Frutos D, Lyoo C . Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry. 2012; 18(8):916-21. PMC: 3594469. DOI: 10.1038/mp.2012.100. View

18.

Sloan M, Klepp T, Gowin J, Swan J, Sun H, Stangl B . The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption. Neuropsychopharmacology. 2018; 43(7):1530-1538. PMC: 5983535. DOI: 10.1038/s41386-017-0002-8. View

19.

Hillard C . Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?. Neuropsychopharmacology. 2017; 43(1):155-172. PMC: 5719092. DOI: 10.1038/npp.2017.130. View

20.

Plawecki M, Decarlo R, Ramchandani V, OConnor S . IMPROVED TRANSFORMATION OF MORPHOMETRIC MEASUREMENTS FOR A PRIORI PARAMETER ESTIMATION IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF ETHANOL. Biomed Signal Process Control. 2008; 2(2):97-110. PMC: 2180397. DOI: 10.1016/j.bspc.2007.04.001. View